BCL2 and hematopoietic and lymphoid system neoplasm: Some clinical assays using Venetoclax, a highly selective oral Bcl-2 inhibitor, have demonstrated apoptosis- or cell death-promoting activity in Bcl-2-dependent, malignant hematological neoplasms, especially cases of chronic lymphocytic leukemia (LLC) [53,54].